Skip to main content

Advertisement

Table 3 Response Rate Data

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

  Cilengitide + Gemcitabine n = 46 Gemcitabine n = 43
  No. patients % No. patients %
Complete response 0 0% 1 2%
Partial response 8 17% 5 12%
Stable disease 17 37% 18 42%
Progressive disease 12 26% 10 23%
Missing/not assessable 9 20% 9 21%
Response rate 8 17% 6 14%
Tumor growth control 25 54% 24 56%